MX2018013428A - Composicion farmaceutica de comprimido en comprimido que comprende ciclofosfamida y capecitabina. - Google Patents
Composicion farmaceutica de comprimido en comprimido que comprende ciclofosfamida y capecitabina.Info
- Publication number
- MX2018013428A MX2018013428A MX2018013428A MX2018013428A MX2018013428A MX 2018013428 A MX2018013428 A MX 2018013428A MX 2018013428 A MX2018013428 A MX 2018013428A MX 2018013428 A MX2018013428 A MX 2018013428A MX 2018013428 A MX2018013428 A MX 2018013428A
- Authority
- MX
- Mexico
- Prior art keywords
- tablet
- capecitabine
- cyclophosphamide
- pharmaceutical composition
- tablet pharmaceutical
- Prior art date
Links
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 title abstract 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 title abstract 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004117 capecitabine Drugs 0.000 title abstract 2
- 229960004397 cyclophosphamide Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940000425 combination drug Drugs 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica de comprimido en comprimido estable que comprende combinaciones en dosis fija de ciclofosfamida y 5 capecitabina y uno o más excipientes farmacéuticamente aceptables, proceso para su preparación y su uso en el tratamiento de enfermedades cancerosas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201621015342 | 2016-05-03 | ||
| PCT/IB2017/052534 WO2017191553A1 (en) | 2016-05-03 | 2017-05-02 | Tablet-in-tablet pharmaceutical composition comprising cyclophosphamide and capecitabine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018013428A true MX2018013428A (es) | 2019-10-07 |
Family
ID=60202819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013428A MX2018013428A (es) | 2016-05-03 | 2017-05-02 | Composicion farmaceutica de comprimido en comprimido que comprende ciclofosfamida y capecitabina. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20190142755A1 (es) |
| EP (1) | EP3452054A4 (es) |
| CN (1) | CN109195609A (es) |
| AU (1) | AU2017260751A1 (es) |
| BR (1) | BR112018072583A2 (es) |
| CA (1) | CA3022799A1 (es) |
| MX (1) | MX2018013428A (es) |
| SG (1) | SG11201809658UA (es) |
| WO (1) | WO2017191553A1 (es) |
| ZA (1) | ZA201808051B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021245519A1 (en) * | 2020-06-01 | 2021-12-09 | Shilpa Medicare Limited | Fast dispersible pharmaceutical composition comprising capecitabine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5047246A (en) * | 1988-09-09 | 1991-09-10 | Bristol-Myers Company | Direct compression cyclophosphamide tablet |
| WO2015044961A2 (en) * | 2013-09-30 | 2015-04-02 | Intas Pharmaceuticals Limited | Pharmaceutical composition comprising capecitabine and cyclophosphamide |
| AR100820A1 (es) * | 2014-06-12 | 2016-11-02 | Sanofi-Synthelabo (India) Ltd | Formulaciones de comprimido bi-capa de ciclofosfamida y capecitabina y administración metronómica altamente fraccionada de las mismas |
| US10016447B2 (en) * | 2014-09-26 | 2018-07-10 | Intas Pharmaceuticals Ltd. | Pharmaceutical composition having improved content uniformity |
| CN106822155B (zh) * | 2016-12-29 | 2019-10-11 | 东北制药集团股份有限公司 | 依非韦伦、拉米夫定及富马酸替诺福韦酯三联复方片中片及其制备方法 |
-
2017
- 2017-05-02 MX MX2018013428A patent/MX2018013428A/es unknown
- 2017-05-02 CN CN201780032891.0A patent/CN109195609A/zh active Pending
- 2017-05-02 WO PCT/IB2017/052534 patent/WO2017191553A1/en unknown
- 2017-05-02 SG SG11201809658UA patent/SG11201809658UA/en unknown
- 2017-05-02 AU AU2017260751A patent/AU2017260751A1/en not_active Abandoned
- 2017-05-02 EP EP17792578.1A patent/EP3452054A4/en not_active Withdrawn
- 2017-05-02 US US16/099,088 patent/US20190142755A1/en not_active Abandoned
- 2017-05-02 CA CA3022799A patent/CA3022799A1/en not_active Abandoned
- 2017-05-02 BR BR112018072583-8A patent/BR112018072583A2/pt not_active Application Discontinuation
-
2018
- 2018-11-28 ZA ZA2018/08051A patent/ZA201808051B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201808051B (en) | 2020-05-27 |
| US20190142755A1 (en) | 2019-05-16 |
| AU2017260751A1 (en) | 2018-11-22 |
| EP3452054A4 (en) | 2019-12-25 |
| CA3022799A1 (en) | 2017-11-09 |
| CN109195609A (zh) | 2019-01-11 |
| SG11201809658UA (en) | 2018-11-29 |
| BR112018072583A2 (pt) | 2019-02-19 |
| WO2017191553A1 (en) | 2017-11-09 |
| EP3452054A1 (en) | 2019-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502251A1 (en) | Formulations of an lsd1 inhibitor | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| SG10201907164SA (en) | Rna containing composition for treatment of tumor diseases | |
| PH12016501394A1 (en) | Compounds for treating patients with ros1 mutant cancer cells | |
| MX2021002321A (es) | Nuevos metodos. | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| IN2014MU00303A (es) | ||
| MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
| PH12017501625A1 (en) | Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease | |
| PH12016502243A1 (en) | Pharmaceutical compositions for treating infectious diseases | |
| PH12020500099A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor | |
| MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
| MY186134A (en) | Curcumin-peptide conjugates and formulations thereof | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| PH12020500096A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor | |
| MX2018014129A (es) | Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato. | |
| MY197685A (en) | Use of a pharmaceutical composition in the manufacture of a medicament for treating a malignant pleural effusions | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| IN2013MU03118A (es) | ||
| MX2018013428A (es) | Composicion farmaceutica de comprimido en comprimido que comprende ciclofosfamida y capecitabina. | |
| MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. | |
| MX2018004774A (es) | Derivados de morfolina sustituidos que tienen actividad contra el dolor. | |
| EA201892675A1 (ru) | Фармацевтическая композиция, содержащая этеплирсен | |
| UA109242U (uk) | Стабільна фармацевтична композиція, що містить інгібітор протеасом |